Alyeska Investment Group L.P. Has $12.32 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

Key Points

• Alyeska Investment Group L.P. increased its position in Xenon Pharmaceuticals Inc. by 27.1% during Q1, purchasing an additional 78,390 shares, bringing its total holdings to 367,233 shares valued at approximately $12.3 million.
• Recently, a majority of analysts rated Xenon Pharmaceuticals as a “Buy”, with a consensus target price of $53.30, although some firms reduced their price objectives.
• Xenon Pharmaceuticals reported a quarterly EPS of ($1.07), missing analyst estimates of ($1.03), marking a decrease from the previous year's quarterly earnings.

Alyeska Investment Group L.P. increased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 27.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 367,233 shares of the biopharmaceutical company's stock after acquiring an additional 78,390 shares during the quarter. Alyeska Investment Group L.P. owned 0.48% of Xenon Pharmaceuticals worth $12,321,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its holdings in shares of Xenon Pharmaceuticals by 2.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,914,749 shares of the biopharmaceutical company's stock valued at $64,240,000 after acquiring an additional 51,276 shares during the period. ADAR1 Capital Management LLC raised its holdings in shares of Xenon Pharmaceuticals by 152.3% during the first quarter. ADAR1 Capital Management LLC now owns 127,548 shares of the biopharmaceutical company's stock valued at $4,279,000 after acquiring an additional 77,001 shares during the period. Vestal Point Capital LP raised its holdings in shares of Xenon Pharmaceuticals by 60.5% during the first quarter. Vestal Point Capital LP now owns 1,300,000 shares of the biopharmaceutical company's stock valued at $43,615,000 after acquiring an additional 490,000 shares during the period. Birchview Capital LP raised its holdings in shares of Xenon Pharmaceuticals by 110.0% during the first quarter. Birchview Capital LP now owns 21,000 shares of the biopharmaceutical company's stock valued at $705,000 after acquiring an additional 11,000 shares during the period. Finally, MPM Bioimpact LLC increased its stake in Xenon Pharmaceuticals by 53.8% in the 1st quarter. MPM Bioimpact LLC now owns 303,398 shares of the biopharmaceutical company's stock valued at $10,179,000 after buying an additional 106,186 shares during the period. Institutional investors and hedge funds own 95.45% of the company's stock.

Xenon Pharmaceuticals Stock Down 0.8%

XENE stock traded down $0.31 during trading hours on Wednesday, hitting $37.20. The company's stock had a trading volume of 173,085 shares, compared to its average volume of 874,768. The company has a market capitalization of $2.87 billion, a PE ratio of -10.47 and a beta of 1.17. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $46.00. The stock has a 50 day moving average price of $34.77 and a two-hundred day moving average price of $33.90.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period in the prior year, the company earned ($0.75) EPS. Sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, May 13th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 2nd. Wall Street Zen lowered shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price objective on the stock. Finally, Wells Fargo & Company assumed coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, September 3rd. They issued an "overweight" rating and a $48.00 price objective on the stock. Eleven research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $53.30.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.